Key Developments: OXiGENE Inc (OXGN.O)

OXGN.O on Consolidated Issue listed on NASDAQ Capital Market

2.23USD
15 Sep 2014
Price Change (% chg)

$-0.04 (-1.76%)
Prev Close
$2.27
Open
$2.29
Day's High
$2.29
Day's Low
$2.16
Volume
225,130
Avg. Vol
371,230
52-wk High
$5.40
52-wk Low
$1.96

Search Stocks

Latest Key Developments (Source: Significant Developments)

Oxigene announces $16 mln at-the-market registered direct offering
Friday, 23 May 2014 09:00am EDT 

Oxigene Inc:Enters into definitive agreements with institutional investors to purchase an aggregate of $16 mln of registered shares of OXiGENE common stock in an at-the-market direct offering at $ 2.9625 per share.Closing of the offering is expected to take place on or about May 28.H.C. Wainwright & Co., LLC acted as the exclusive placement agent in connection with this offering.  Full Article

Oxigene appoints President and Chief Executive Officer
Friday, 16 May 2014 08:30am EDT 

Oxigene Inc:Appoints David (Dai) Chaplin to the position of President and Chief Executive Officer replacing Peter Langecker.  Full Article

OXiGENE Inc announces positive topline results from randomized phase 2 study GOG186I of Zybrestat in combination with Avastin for recurrent ovarian cancer
Tuesday, 11 Mar 2014 03:36pm EDT 

OXiGENE Inc:Announced positive results from a randomized Phase 2 clinical trial evaluating Avastin (bevacizumab) with or without ZYBRESTAT (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer.Says the Study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival.Phase 2 study is being conducted by the GOG under the sponsorship of the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute.  Full Article

Oxigene Inc announces $12 million public offering
Wednesday, 12 Feb 2014 08:56am EST 

Oxigene Inc:Enters into definitive agreements with investors to purchase an aggregate of about $12 million of units, in a registered public offering, at a price per unit of $2.05.Each unit consists of one share of common stock and 0.5 of a warrant to purchase a share of OXiGENE common stock.The warrants have an exercise price of $2.75 per share, shall be exercisable immediately and will expire five years from the date of issuance. The closing of the offering is expected to take place on or about Feb. 18.  Full Article

Oxigene Inc announces appointment of chairman-Form 8-K
Wednesday, 27 Nov 2013 04:35pm EST 

Oxigene Inc:Says on Nov. 22, the Board of the company increased the size of the Board by one, from five to six members, and approved the election of Frederick W. Driscoll to fill the newly created , effective Jan. 1, 2014.Says Driscoll was also named Chairman of the Board and appointed to the Board’s Audit Committee.  Full Article

Oxigene Inc Announces $5.8 Million Private Placement
Thursday, 19 Sep 2013 12:40pm EDT 

Oxigene Inc announced that it has entered into definitive agreements with institutional accredited investors in a private placement of $5.8 million of zero coupon series B convertible preferred stock (which are convertible into a total of approximately 2.45 million shares of common stock) and a series of warrants potentially exercisable for up to approximately 2.45 million additional shares of common stock, in the aggregate. In addition to the preferred stock not having a required dividend right or voting rights, the preferred stock will not have any preferences over the Company's common stock, including liquidation rights. The offering is expected to close on or about September 20, 2013, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. acted as the exclusive placement agent for the transaction.  Full Article

Faruqi & Faruqi, LLP Launches Investigation Against OXiGENE Inc For Potential Breaches Of Fiduciary Duties By Board Of Directors
Tuesday, 18 Jun 2013 07:00pm EDT 

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a national securities firm headquartered in New York City, announced that it is investigating the Board of Directors of OXiGENE, Inc. for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders` approval for an amendment to the Company`s 2005 Stock Plan. Specifically, in the Proxy Statement filed by the Company with the Securities and Exchange Commission on June 13, 2013, the Board of Directors recommends that OXiGENE`s shareholders vote to approve an amendment to the Company`s 2005 Stock Plan to increase the number of shares of OXiGENE common stock reserved for issuance thereunder from 333,333 shares to 833,333 shares. The issuance of the additional shares could have a substantial dilutive effect on the shares of OXiGENE common stock.  Full Article

Oxigene Inc Announces $5 Million Private Placement
Thursday, 11 Apr 2013 08:30am EDT 

Oxigene Inc announced that it has entered into definitive agreements with institutional accredited investors in a private placement of $5.0 million of zero coupon convertible preferred stock (which are convertible into a total of approximately 1.38 million shares of common stock) and 2 series of warrants potentially exercisable for up to approximately 2.76 million additional shares of common stock, in the aggregate. In addition to the preferred stock not having a required dividend right, the preferred stock will not have any preferences over the Company's common stock, including liquidation rights. Subject to certain ownership limitations, the preferred stock is convertible at any time at the option of the holder into shares of common stock at a conversion price of $3.63 (which represents a price above the closing price of the common stock on the previous trading day). The first series of warrants will allow for the investors to purchase up to approximately 1.38 million shares of common stock at an exercise price of $3.40 per share and are exercisable for 5 years. The second series of warrants will allow for the investors to purchase up to approximately 1.38 million shares of common stock at an exercise price of $3.40 per share and are exercisable for 2 years. OXiGENE has agreed to register the resale of the shares of common stock issuable upon conversion of the preferred stock and upon exercise of the warrants. The offering is expected to close on or about April 12, 2013.  Full Article

Oxigene Inc Announces Appointment Of CFO-Form 8-K
Thursday, 28 Feb 2013 10:27pm EST 

Oxigene Inc reported in its Form 8-K that on February 27, 2013, the Board of Directors of OXiGENE, Inc. (Company) appointed Barbara Riching as the Company’s Chief Financial Officer (CFO).  Full Article

Search Stocks